CGEM Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (CGEM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 58% planned / 42% discretionary
Largest single sale: $607.8K.
Where they traded
Last open-market purchase: October 28, 2025 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 8,000 | $21.57 | $172.6K | 158,844 −4.8% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 30,000 | $20.26 | $607.8K | 162,844 −15.6% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 8,000 | $17.82 | $142.6K | 162,844 −4.7% of holding | |
| Michaelson Jennifer 2 fills | Chief Scientific Officer | Sell 10b5-1 | 8,000 | $14.62 | $117.0K | 167,044 −4.6% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 8,000 | $15.68 | $125.4K | 170,844 −4.5% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 1,780 | $14.14 | $25.2K | 174,844 −1% of holding | |
| AHMED NADIM | President and CEO | Sell | 13,515 | $14.47 | $195.6K | 390,803 −3.3% of holding | |
| Jones Jeffrey Alan | Chief Medical Officer | Sell | 4,582 | $14.47 | $66.3K | 159,968 −2.8% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell | 3,601 | $14.47 | $52.1K | 176,624 −2% of holding | |
| SUMER JACQUELYN L | Chief Legal Officer | Sell | 3,601 | $14.47 | $52.1K | 128,089 −2.7% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 1,752 | $13.99 | $24.5K | 180,225 −1% of holding | |
| AHMED NADIM | President and CEO | Sell | 16,381 | $13.62 | $223.1K | 404,318 −3.9% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 8,000 | $14.30 | $114.4K | 181,977 −4.2% of holding | |
| Jones Jeffrey Alan | Chief Medical Officer | Sell | 4,982 | $13.62 | $67.9K | 164,550 −2.9% of holding | |
| Fenton Mary Kay | Chief Financial Officer | Sell | 4,398 | $13.62 | $59.9K | 126,380 −3.4% of holding | |
| SUMER JACQUELYN L | Chief Legal Officer | Sell | 3,742 | $13.62 | $51.0K | 131,690 −2.8% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell | 3,742 | $13.62 | $51.0K | 181,977 −2% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell | 416 | $12.03 | $5.0K | 128,219 −0.3% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $12.30 | $49.2K | 128,635 −3% of holding | |
| AHMED NADIM | President and CEO | Sell | 9,922 | $10.01 | $99.3K | 420,699 −2.3% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 1,345 | $10.01 | $13.5K | 132,635 −1% of holding | |
| Jones Jeffrey Alan | Chief Medical Officer | Sell | 4,632 | $9.67 | $44.8K | 169,532 −2.7% of holding | |
| SUMER JACQUELYN L | Chief Legal Officer | Sell | 3,480 | $9.67 | $33.7K | 135,432 −2.5% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell | 2,898 | $9.67 | $28.0K | 133,980 −2.1% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 995 | $11.90 | $11.8K | 136,878 −0.7% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell | 2,148 | $12.38 | $26.6K | 137,873 −1.5% of holding | |
| Michaelson Jennifer | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $12.30 | $49.2K | 138,004 −2.8% of holding | |
| Buy | 165,667 | $8.40 | $1.4M | 8,963,500 | |||
| Buy | 32,217 | $7.84 | $252.6K | 8,797,833 | |||
| Buy | 150,000 | $8.86 | $1.3M | 8,765,616 | |||
| Buy | 51,500 | $7.94 | $409.0K | 8,615,616 | |||
| Buy | 15,032 | $7.59 | $114.0K | 8,564,116 | |||
| Buy | 277,298 | $7.36 | $2.0M | 8,549,084 | |||
| Buy | 626,043 | $6.70 | $4.2M | 8,271,786 | |||
| Buy | 556,300 | $6.46 | $3.6M | 7,645,743 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.